WASHINGTON--(BUSINESS WIRE)--Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.

华盛顿--（商业新闻短讯）--总部位于华盛顿特区的整形外科设备生物技术公司Nanochon在其系列seed prime融资回合中筹集了400万美元。

The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others.

这一轮由弗吉尼亚大学许可和风险投资集团种子基金牵头，参与者包括Travel（MD）、校友风险投资集团和Mountain State Capital等。

Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.

Nanochon打算利用这些资金于2024年在美国启动其首次人体临床试验，深化研究和开发工作，扩大公司的专利概况并壮大其团队。

“We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.”

首席执行官兼联合创始人本·霍姆斯（BenHolmes）表示：“我们很高兴结束融资回合，开始我们的临床项目。”。“获得这笔资金是朝着实现Nanochon消除膝关节置换需求的目标迈进了一步，并大大改变了关节炎关节护理的模式。”

Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilage and bone to stave off the need for full knee replacements which are costly and have a long recovery time.

Nanochon今年将在美国启动其专利膝关节植入软骨移植™的I期临床试验。该设备只需要微创手术即可再生受损的软骨和骨骼，从而避免了昂贵且恢复时间长的全膝关节置换术的需要。

Holmes follows, “We’ve had fantastic success in our animal studies and we’re very optimistic about future implications in human knees and other joints.”

霍姆斯说：“我们在动物研究中取得了巨大的成功，我们对人类膝盖和其他关节的未来影响非常乐观。”

Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive implant that allows for immediate weight-bearing and motion – meaning less time spent recovering. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care.

Nanochon是一家生物技术和医疗器械公司，专注于开发创新的骨科解决方案。软骨移植™是一种微创植入物，可以立即负重和运动，这意味着恢复所需的时间更少。与目前的护理标准相比，Nanochon有可能为患者提供更成功和更持久的恢复。

Our mission is to develop a new approach to treat cartilage replacement and repair so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without having to undergo costly and invasive short-term fixes..

我们的使命是开发一种治疗软骨置换和修复的新方法，使数十万年轻活跃的关节损伤患者能够恢复生活方式，而无需进行昂贵且侵入性的短期修复。。